COMPARISON OF METHOTREXATE AND APREMILAST COMBINATION WITH METHOTREXATE ALONE IN PALMOPLANTAR PSORIASIS
Not Applicable
- Conditions
- Health Condition 1: L408- Other psoriasis
- Registration Number
- CTRI/2020/07/026379
- Lead Sponsor
- nil
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Histopathologically and dermoscopically proven Palmoplantar psoriasis with mPPASI > 10, DLQI > 3
Exclusion Criteria
1.Deranged CBC, LFT, urea, creatinine
2.Pregnancy, lactation
3.Alcoholics
4.Palmoplantar pustulosis
5.Concomitant plaque psoriasis involving sites other than knuckles and nails; erythrodermic and pustular psoriasis, and psoriatic arthritis requiring concomitant systemic anti-psoriatic treatments.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method i)To assess the response to treatment with systemic methotrexate vs methotrexate and apremilast in patients with Palmolplantar psoriasis <br/ ><br>ii) To investigate the correlation between clinical severity of Palmoplantar Psoriasis and patientsâ?? quality of life by using DLQI <br/ ><br>Timepoint: Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks
- Secondary Outcome Measures
Name Time Method ii) To investigate the correlation between clinical severity of Palmoplantar Psoriasis and patientsâ?? quality of life by using DLQI <br/ ><br>Timepoint: 4 months